EDAP Quote, Financials, Valuation and Earnings

Biodexa Pharmaceuticals PLC has a net margin of -9.55% compared to Edap TMS SA's net margin of --. Edap TMS SA's return on equity of -39.5% beat Biodexa Pharmaceuticals PLC's return on equity of -160.77%.

Edap TMS SA has a consensus price target of $10.50, signalling upside risk potential of 388.37%. On the other hand Biodexa Pharmaceuticals PLC has an analysts' consensus of $17.97 which suggests that it could grow by 1370.86%. Given that Biodexa Pharmaceuticals PLC has higher upside potential than Edap TMS SA, analysts believe Biodexa Pharmaceuticals PLC is more attractive than Edap TMS SA.

Edap TMS SA has a beta of 0.372, which suggesting that the stock is 62.782% less volatile than S&P 500. In comparison Biodexa Pharmaceuticals PLC has a beta of 1.489, suggesting its more volatile than the S&P 500 by 48.943%.

Edap TMS SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biodexa Pharmaceuticals PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Edap TMS SA pays -- of its earnings as a dividend. Biodexa Pharmaceuticals PLC pays out -- of its earnings as a dividend.

Edap TMS SA quarterly revenues are $21.7M, which are larger than Biodexa Pharmaceuticals PLC quarterly revenues of --. Edap TMS SA's net income of -$2.1M is higher than Biodexa Pharmaceuticals PLC's net income of --. Notably, Edap TMS SA's price-to-earnings ratio is -- while Biodexa Pharmaceuticals PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Edap TMS SA is 1.16x versus 1.11x for Biodexa Pharmaceuticals PLC. Usually stocks with elevated PS ratios are considered overvalued.

DBV Technologies SA has a net margin of -9.55% compared to Edap TMS SA's net margin of --. Edap TMS SA's return on equity of -39.5% beat DBV Technologies SA's return on equity of --.

Edap TMS SA has a consensus price target of $10.50, signalling upside risk potential of 388.37%. On the other hand DBV Technologies SA has an analysts' consensus of $22.63 which suggests that it could grow by 264.99%. Given that Edap TMS SA has higher upside potential than DBV Technologies SA, analysts believe Edap TMS SA is more attractive than DBV Technologies SA.

Edap TMS SA has a beta of 0.372, which suggesting that the stock is 62.782% less volatile than S&P 500. In comparison DBV Technologies SA has a beta of 0.707, suggesting its less volatile than the S&P 500 by 29.271%.

Edap TMS SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. DBV Technologies SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Edap TMS SA pays -- of its earnings as a dividend. DBV Technologies SA pays out -- of its earnings as a dividend.

Edap TMS SA quarterly revenues are $21.7M, which are larger than DBV Technologies SA quarterly revenues of --. Edap TMS SA's net income of -$2.1M is higher than DBV Technologies SA's net income of -$23M. Notably, Edap TMS SA's price-to-earnings ratio is -- while DBV Technologies SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Edap TMS SA is 1.16x versus -- for DBV Technologies SA. Usually stocks with elevated PS ratios are considered overvalued.

Evaxion Biotech AS has a net margin of -9.55% compared to Edap TMS SA's net margin of -64.14%. Edap TMS SA's return on equity of -39.5% beat Evaxion Biotech AS's return on equity of --.

Edap TMS SA has a consensus price target of $10.50, signalling upside risk potential of 388.37%. On the other hand Evaxion Biotech AS has an analysts' consensus of $13.25 which suggests that it could grow by 652.84%. Given that Evaxion Biotech AS has higher upside potential than Edap TMS SA, analysts believe Evaxion Biotech AS is more attractive than Edap TMS SA.

Edap TMS SA has a beta of 0.372, which suggesting that the stock is 62.782% less volatile than S&P 500. In comparison Evaxion Biotech AS has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Edap TMS SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Evaxion Biotech AS offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Edap TMS SA pays -- of its earnings as a dividend. Evaxion Biotech AS pays out -- of its earnings as a dividend.

Edap TMS SA quarterly revenues are $21.7M, which are larger than Evaxion Biotech AS quarterly revenues of $3M. Edap TMS SA's net income of -$2.1M is lower than Evaxion Biotech AS's net income of -$1.9M. Notably, Edap TMS SA's price-to-earnings ratio is -- while Evaxion Biotech AS's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Edap TMS SA is 1.16x versus 0.49x for Evaxion Biotech AS. Usually stocks with elevated PS ratios are considered overvalued.

NuCana PLC has a net margin of -9.55% compared to Edap TMS SA's net margin of --. Edap TMS SA's return on equity of -39.5% beat NuCana PLC's return on equity of --.

Edap TMS SA has a consensus price target of $10.50, signalling upside risk potential of 388.37%. On the other hand NuCana PLC has an analysts' consensus of $64.50 which suggests that it could grow by 4939.06%. Given that NuCana PLC has higher upside potential than Edap TMS SA, analysts believe NuCana PLC is more attractive than Edap TMS SA.

Edap TMS SA has a beta of 0.372, which suggesting that the stock is 62.782% less volatile than S&P 500. In comparison NuCana PLC has a beta of 0.892, suggesting its less volatile than the S&P 500 by 10.789%.

Edap TMS SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NuCana PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Edap TMS SA pays -- of its earnings as a dividend. NuCana PLC pays out -- of its earnings as a dividend.

Edap TMS SA quarterly revenues are $21.7M, which are larger than NuCana PLC quarterly revenues of --. Edap TMS SA's net income of -$2.1M is lower than NuCana PLC's net income of -$836.1K. Notably, Edap TMS SA's price-to-earnings ratio is -- while NuCana PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Edap TMS SA is 1.16x versus -- for NuCana PLC. Usually stocks with elevated PS ratios are considered overvalued.